{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-072304","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.423710+00:00","generated_at":"2026-06-13T23:18:29.905828+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Nuvectis Pharma shareholders approve equity plan amendment increasing shares by 1M","bullets":["Stockholders approved amendment to Global Equity Incentive Plan (2021) adding 1,000,000 shares and annual evergreen from 2024-2033.","Ron Bentsur re-elected as Class I director with 9,035,321 votes for, 149,868 withheld, and 3,284,985 broker non-votes.","Ratification of Kesselman & Kesselman as independent auditor for FY 2023 approved with 12,468,118 for, 616 against, 1 abstention."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-072304","json":"https://secwatch.observer/filing/0001104659-23-072304.json","markdown":"https://secwatch.observer/filing/0001104659-23-072304.md","text":"https://secwatch.observer/filing/0001104659-23-072304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/0001104659-23-072304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/tm2318992d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T23:18:29.905828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc2e941985b9ae2173407ede60232c35420d44ce","claim":"Nuvectis Pharma, Inc. shareholders approved Approval of amendment to Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021) at the 2023-06-16 meeting.","evidence_excerpt":"The vote with respect to the approval of an amendment to the Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021) was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 8,984,698 198,029 2,462 3,284,985","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/0001104659-23-072304-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"e061e9cfea87bebea796a2e8aaa049ffb369a19b","claim":"Nuvectis Pharma, Inc. shareholders approved Ratification of Kesselman & Kesselman as independent registered public accounting firm at the 2023-06-16 meeting.","evidence_excerpt":"The vote with respect to the ratification of Kesselman & Kesselman as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 12,468,118 616 1,440 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/0001104659-23-072304-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"e2a74b8c16d45ce2f054e92543ec6e000b2e2335","claim":"Nuvectis Pharma, Inc. shareholders approved Election of Class I director at the 2023-06-16 meeting.","evidence_excerpt":"The votes with respect to the election of the Class I director to hold office until the 2026 annual meeting were as follows: Director Votes For Votes Withheld Broker Non-Votes Ron Bentsur 9,035,321 149,868 3,284,985","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/0001104659-23-072304-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}